Atea Pharmaceuticals Advances HCV Treatment with Ongoing Phase 3 C-BEYOND Trial and Promising Phase 2 Results for Bemnifosbuvir and Ruzasvir at EASL 2025
12/5 22:22
Atea Pharmaceuticals reports progress on HCV treatment trials and upcoming investor event featuring clinical insights on their antiviral regimen....